The responsiveness of plasma homocysteine to small increases in dietary folic acid: A primary care study

European Journal of Clinical Nutrition

Volumn 52, Issue 6, 1998, Pages 407-411

  Schorah, C J ^a   Devitt, H ^a   Lucock, M ^a   Dowell, A C ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Folic acid; Homocysteine; Occlusive vascular disease

Indexed keywords

CYANOCOBALAMIN; CYSTEINE; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CEREAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ERYTHROCYTE; FEMALE; FOLIC ACID BLOOD LEVEL; GENERAL PRACTICE; HUMAN; MALE; NORMAL HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RESEARCH; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0031749766     PISSN: 09543007     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1600576     Document Type: Article

References (34)

1. Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Anderson A & Nilsson-Ehle P(1993): The effect of high dose, pyrid-oxide and folic acid supplementation on serum lipid and plasma homocysteine concentration in dialysis patients. Clin. Nephrol. 40, 236-240.
2. Bergmark C, Mansoor MA, Swedonborg J, de Faire V, Svardal AM & Ueland PM (1993): Hyperhomocysteinaemia in patients operated for lower extremity ischaemia below the age of 50: effect of smoking and extent of disease. Eur. J. Vasc. Surg. 7, 391-396.
3. Boers GH (1994): Hyperhomocysteinaemia: a newly recognised risk factor for vascular disease. Neth. J. Med. 45, 34-41.
4. Boushey CJ, Beresford SA, Omenn GS & Motulsky AG (1995): A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J. Am. Med. Ass. 274, 1049-1057.
5. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B & Hamfelt A (1992): Hyperhomocysteinaemia in stroke: prevalence, cause and relationships to type of stroke and stroke risk factors. Eur. J. Clin. Invest. 22, 214-221.
6. Brattström LE, Hultberg BL & Hardebo JE (1985): Folic acid responsive post-menopausal homocysteinaemia. Metabolism 34, 1073-1077.
7. Chanarin I (1994): Adverse effects of increased dietary folate. Relation to measures to reduce the incidence of neural tube defects. Clin. Invest. Med. 17, 244-252.
8. Clarke R, Daly L, Robinson K, Waughton E, Cahalane S, Fowler B & Graham I (1991): Hyperhomocysteinaemia: an independent risk factor for vascular disease. New Engl. J. Med. 324, 1149-1155.
9. Daly S, Mills JL, Molloy AM, Conley M, Lee YJ, Kirke PN, Weir DG & Scott JM (1997): Minimum effective dose of folic acid for food fortification to prevent neural tube defects. Lancet 350, 1666-1669.
10. Daskalakis I, Lucock MD, Anderson A, Wild J, Schorah CJ & Levene MI (1996): Determination of plasma total homocysteine and cysteine using HPLC with fluorescence detection and an ammonium 7-fluoro-2,1,3-benzoxadiazole-4-sulphonate (SBD-F) derivatization protocol optimised for antioxidant concentration, derivatization reagent concentra-tion, temperature and matrix pH. Biomed. Chromatogr. 10, 205-212.
11. Department of Health (1991): Dietary reference values for food, energy and nutrients for the United Kingdom. Report on Health and Social Subjects 41. London: HMSO.
12. Diagnostic Products Corporation. Folate measurements using a dual count solid phase Boil Assay. Los Angeles, USA.
13. Dickinson CJ (1995): Does folic acid harm people with B12 deficiency?. QJM 88, 357-364.
14. Guttormsen AB, Ueland PM, Nasthus I, Nygard O, Schneede J, Vollset SE & Refsum H (1996): Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or =40μmol/litre). The Hordaland Homocysteine Study. J. Clin. Invest. 98, 2174-2183.
15. Israelsson B, Brattström LE & Hultberg BJ (1988): Homocysteine and myocardial infarction. Atherosclerosis 71, 227-233.
16. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Seek M, Otto JM & Taylor LM (1994): Rapid HPLC determination of total homocysteine and other thiols in serum and plasma. Clin. Chem. 40, 873-881.
17. Lewis CA, Pancharuniti N & Sauberlich HC (1992): Plasma folate adequacy as determined by homocysteine level. Ann. NY Acad. Sci. 669, 360-362.
18. Malinow MR (1990): Hyperhomocysteinaemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 81, 2004-2006.
19. Masser PA, Taylor LM & Porter JM (1994): Importance of elevated plasma homocysteine levels as a risk factor for atherosclerosis. Ann. Thoracic Surg. 58, 1240-1246.
20. Molgaard J, Malinow MR, Lassuik C, Holm AC, Upson B & Olsson AG (1992): Hyperhomocysteinaemia: an independent risk factor for intermittent claudication. J. Int. Med. 231, 273-279.
21. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M & Vollset SE (1997): Plasma homocysteine levels and mortality in patients with coronary artery disease. New Engl. J. Med. 337, 260-236.
22. Oakley GP, Adams MJ & Dickinson CM (1996): More folic acid for everyone, now. J. Nutr. 126, 751S-755S.
23. Olszewski AJ, Szostak WB, Bialowska M & Rudnicki S (1989): Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin and troxerutin in atherosclerosis. Atherosclerosis 75, 1-6.
24. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RC, Alvarez JO, Macaluso M, Acton RT, Copeland RB & Cousins AL (1994): Plasma homocysteine, folate and vitamin B12 concentrations and risk for early onset coronary artery disease. Am. J. Clin. Nutr. 59, 940-948.
25. Schorah CJ & Wild J (1993): Fortified foods and folate intake in women of child-bearing age. Lancet 341, 1417.
26. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Rush D, Schaefer EJ & Rosenberg IH (1996): Relationship between plasma homocysteine, vitamin status and extracranial carotid-artery stenosis in the Framingham Study population. J. Nutr. 126, 1258S-1265S.
27. Selhub J, Jacques PF, Wilson PWF, Rush D & Rosenberg IH (1993): Vitamin status and intake as primary determinants of homocysteinaemia in an elderly population. J. Am. Med. Ass. 270, 2693-2698.
28. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler DV & Hennekens CH (1992): A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J. Am. Med. Ass. 268, 877-881.
29. Taylor L, DeFrang RD, Harris EJ & Portor JM (1991): The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease. J. Vasc. Surg. 13, 128-136.
30. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ, Delport R & Potgieter HC (1994): Vitamin requirements for the treatment of hyperhomocysteinemia. J. Nutr. 124, 1927-1933.
31. Ueland PM, Refsum H & Brattström L (1992): Plasma homocysteine and cardiovascular disease. In Atherosclerosis Cardiovascular Disease, Hemostasis and Endothelial Function, ed. BR Francis, pp 183-235, NY: Marcel Dekker.
32. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH & Willen WC (1996): Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12 and folate. Am J. Epidemiol. 143, 845-859.
33. Ward M, McNulty H, McPartlin JM, Strain JJ, Weir D & Scott JM (1997): The response of plasma homocysteine to low-dose pterogylutamic (folic) acid supplementation in healthy male subjects. Proc. Nutr. Soc. 56, 148A.
34. Wilcken DEL, Dudman NPB, Tyrrell PA & Robertson MR (1988): Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Membolism 31, 697-701.